Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

We conducted a phase 2 study of ruxolitinib in patients with relapsed/refractory leukemias. Patients with acceptable performance status (0-2), adequate organ function, and no active infection, received ruxolitinib 25 mg orally twice a day for 4 weeks (1 cycle). Response was assessed after every 2 cy...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Eghtedar, Alireza, Verstovsek, Srdan, Estrov, Zeev, Burger, Jan, Cortes, Jorge, Bivins, Carol, Faderl, Stefan, Ferrajoli, Alessandra, Borthakur, Gautam, George, Solly, Scherle, Peggy A., Newton, Robert C., Kantarjian, Hagop M., Ravandi, Farhad
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2012
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4081383/
https://ncbi.nlm.nih.gov/pubmed/22422826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-12-400051
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados